<DOC>
	<DOCNO>NCT01550614</DOCNO>
	<brief_summary>The purpose study determine whether single intracoronary infusion Ad5FGF-4 , deliver induced transient ischemia , effective improve myocardial perfusion , angina functional class , patient symptom , quality life . Short-term ( 8 week ) long-term ( 12 month ) safety Ad5FGF-4 also evaluate . The primary endpoint change adenosine triphosphate ( ATP ) stress SPECT reperfusion defect size .</brief_summary>
	<brief_title>Efficacy Safety Ad5FGF-4 Myocardial Ischemia Patients With Stable Angina Due Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<criteria>Patients 1875 year age , inclusive Postmenopausal female patient , woman childbearing potential men willing use effective contraception method study treatment and/or agree become pregnant make partner pregnant throughout study one year administration study drug Female subject childbearing potential negative urine pregnancy test , willing use acceptable form birth control study Diagnostic coronary angiogram past confirm presence coronary artery disease . Patients extensive disease , high risk intervention , n't want high risk angioplasty surgery , angioplasty recurrent angina vessel ideal angioplasty ideal candidate Stable angina pectoris treat chronic antianginal medication ( ) stable dose 2 week prior randomization Left ventricular ejection fraction ( LVEF ) ≥30 % . If LVEF &lt; 30 % patient enrol recent current congestive heart failure present Evidence stress induce myocardial ischemia ATP technetium99m sestamibi SPECT , define reversible perfusion defect size ≥9 % Willing able comply study requirement Provided write informed consent Female patient pregnant , lactate ( breast milk feeding ) , plan pregnancy course study one year administration study drug . Women child bear potential use acceptable method birth control . Women child bear potential positive urine pregnancy test within 24 hour prior start investigational product Patients unstable angina immediate revascularization procedure indicate Patients cardiac revascularization procedure plan next 3 month Myocardial infarction within 3 month prior Screening visit Congestive heart failure NYHA Class IV Myocarditis restrictive pericarditis Left main coronary stenosis ≥70 % ( unless patient patent graft collateral vessel supply leave coronary circulation ) proximal stenosis ≥70 % major coronary conduit vessel ( coronary artery bypass graft ) A single patent coronary conduit ( example , totally occluded RCA LCx bypass graft . Patient tolerate balloon occlusion LAD infusion ) Clinically significant aortic mitral valvular heart disease . Life threaten coronary ostial stenosis precludes adequate catheter engagement target vessel , unless vessel access via patent bypass graft Coronary artery venous communication , bypass coronary capillary bed Untreated lifethreatening ventricular arrhythmia Uncontrolled arterial hypertension systolic blood pressure &gt; 180 mm Hg diastolic pressure &gt; 100 mm Hg CABG surgery within past 6 month , unless graft occlude Percutaneous transluminal coronary angioplasty ( PTCA ) within past 3 month , unless stented/dilated vessel ( ) occlude Enhanced external counterpulsation ( EECP ) within 3 month prior start screen evaluation Transmyocardial percutaneous myocardial laser revascularization within previous year Prior treatment cardiovascular gene therapy Patients receive investigational drug biologic within 30 day screen currently participate investigational drug , biologic device trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Angina Pectoris</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Chest Pain</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Myocardial Perfusion</keyword>
	<keyword>Reversible Perfusion Defect Size</keyword>
	<keyword>SPECT-MIBI</keyword>
	<keyword>Anti-Anginal Medication</keyword>
	<keyword>Quality Life</keyword>
</DOC>